接受脑啡肽酶抑制剂患者的肾脏事件:系统综述与荟萃分析
该系统综述与荟萃分析纳入17项随机对照试验共23 569例患者,比较脑啡肽酶抑制剂联合ACEi/ARB与单用ACEi或ARB的肾脏事件风险。作者认为脑啡肽酶抑制剂联合ACEi/ARB在肾脏不良事件方面是安全的。
核心结论
- 脑啡肽酶抑制剂联合ACEi/ARB在肾脏不良事件方面是安全的。
- 需要更长期、聚焦慢性肾脏病的试验来评估脑啡肽酶抑制剂对减缓CKD进展的作用。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Cochrane、ClinicalTrials.org和Embase,纳入17项随机对照试验(研究药物为沙库巴曲/缬沙坦或奥马曲拉),共23 569例患者。
- 提取所有肾脏终点,包括长期和短期结局及高钾血症,采用DerSimonian and Laird法计算合并比值比(OR)。
- 研究在PROSPERO注册。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长期、聚焦慢性肾脏病的试验来评估脑啡肽酶抑制剂对减缓CKD进展的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns. This meta-analysis aimed to examine the risk for renal events, progression of chronic kidney disease (CKD) or progression to dialysis on combined NEPi and ACEi/ARBs compared with ACEi or ARBs. METHODS: We performed a systematic meta-analysis including 17 randomized controlled trials (study drug sacubitril/valsartan or omapatrilat), involving a total of 23 569 patients, after searching PubMed, Cochrane, ClinicalTrials.org and Embase for eligible studies. From the included trials, all renal endpoints, including long- and short-term outcomes and hyperkalemia, were extracted. Pooled odds ratios (ORs) were calculated using the DerSimonian and Laird method. The study was registered at PROSPERO. RESULTS: Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone. Also, there was a decreased risk of severe acute renal events [OR 0.8 (0.69-0.93)] and a decrease in estimated glomerular filtration rate decline [mean difference -0.58 mL/min (-0.83 to -0.33 mL/min)]. There was no difference in chronic renal events [OR 0.92 (0.8-1.05)] or hyperkalemia [OR 1.02 (0.84-1.23)]. CONCLUSION: NEPi + ACEi/ARBs are safe in terms of renal adverse events. Longer trials focusing on CKD are needed to evaluate the effect of NEPi on decreasing progression of CKD.
引用
- Vollmer Barbosa C, Lang H, Melk A, et al. Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022. PMID: 35022763. doi:10.1093/ndt/gfac001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。